Zacks Investment Research Upgrades Redhill Biopharma Ltd. (RDHL) to Hold

RedHill Biopharma Ltd., launched on August 3, 2009, is a biopharmaceutical company. FBR & Co reissued an "outperform" rating and issued a $25.00 price target (down from $36.00) on shares of RedHill Biopharma Ltd - in a research note on Friday, February 24th. Finally, UBS AG initiated coverage on Redhill Biopharma in a research note on Wednesday, September 13th. The consensus rating is 3, suggesting the market has given up on the stock.

Based on the latest brokerage notes which have been released to investors, 0 brokers have issued a rating of "strong buy", 3 brokers "buy", 0 brokers "neutral", 0 brokers "sell" and 0 brokers "strong sell".

Day traders strive to make money by exploiting minute price movements in individual assets (usually stocks, though currencies, futures and options are traded as well), usually leveraging large amounts of capital to do so, therefore they trade on Stocks in Play.

The share price of the company (RDHL) was up +10.56%, with a high of 10.10 during the day and the volume of Redhill Biopharma Ltd. shares traded was 228773. Outstanding shares refer to a company's stock presently held by all its shareholders, counting share blocks held by institutional shareholders and restricted shares owned by the company's officers and insiders. Current price places the company's stock -27.61% away from its 200-day simple moving average, -15.48%, away from the 50-day average and also -4.6% away from 20-day average. The firm's market capitalization is $185.53 million. RedHill Biopharma Ltd - has a 52-week low of $8.77 and a 52-week high of $16.54.

Shares of Redhill Biopharma (NASDAQ:RDHL) opened at 9.46 on Wednesday.

As of the latest earnings report the EPS was $-2.46 and is expected to be $-2.36 for the current year with 17,163,000 shares now outstanding. The business had revenue of $0.48 million during the quarter, compared to analysts' expectations of $0.34 million. Equities analysts forecast that Redhill Biopharma will post ($2.36) EPS for the current fiscal year. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of United States & worldwide copyright & trademark laws. If you are viewing this story on another domain, it was stolen and republished in violation of United States and worldwide copyright law.

Current levels places RedHill Biopharma Ltd. (NASDAQ:RDHL)'s stock about -1.28% from the 50-day high and 32.20% away from the 50-day low. Investors might also notice that three month ago the Buy recommendations (3) outnumbered Sell recommendations (0). Family Management Corp lifted its stake in shares of Redhill Biopharma by 51.5% in the 2nd quarter. Family Management Corp claims 25,750 shares worth $222,000. Oppenheimer & Co. Inc. raised its position in shares of Redhill Biopharma by 10.8% during the second quarter. Oppenheimer & Co. Inc. now owns 25,569 shares of the biotechnology company's stock worth $220,000 after acquiring an additional 2,500 shares during the period. Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the 1st quarter worth approximately $101,000. Bank of New York Mellon Corp now owns 12,005 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 1,440 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Redhill Biopharma during the first quarter worth $276,000.

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company.

Like this



30 September 2017
South Korea Wants Wartime Control of its Military
When the South has wartime operation control, the North will fear us more, and the people will trust our armed forces more. The comments came after a meeting between President Moon and the leaders of four major political parties.

30 September 2017
Insiders Selling, Short Interest Growing Ormat Technologies, Inc. (NYSE:ORA)
Oppenheimer has "Buy" rating and $65 target. (NYSE:ORA) has "Mkt Outperform" rating given on Monday, December 19 by Avondale. The company's shares were given away at $59.5 per share worth to an income of some $685,619 on account of Argas Shlomi.

30 September 2017
Two men killed, multiple injured in Bronx apartment fire
EMS responded to the location and transported the victim to Jacobi Hospital, where he was pronounced dead. Two men were killed and five others were injured after a fire broke out in a Bronx apartment.

30 September 2017
New Stranger Things Photos Reveal Changes to Come
The Duffers and executive producer Shawn Levy have now said that it might go beyond four seasons, according to EW. Netflix's smash hit Stranger Things became an instant pop culture phenomenon after its debut last July.

30 September 2017
N.Korea mobilises aircraft in response to U.S. bombers
Analysts say North Korea may be trying to create a distraction as it works to advance its nuclear weapons development. Moon has been more aggressive than his conservative predecessors about building up the South Korean military.

30 September 2017
Madonna uses $600 mask on her butt to keep the skin soft
She is clearly proud of the skincare line , which she co-developed with Japanese company MTG and her own dermatologist, Dr. Don't other people look at your butt? "It's a little bit weird".

30 September 2017
Axa Sells 31100 Shares of WW Grainger, Inc. (NYSE:GWW)
It has underperformed by 37.85% the S&P500. (NYSE:GWW) shares have been seen trading 5.53% away from the 20-day moving average. Flossbach Von Storch Ag decreased Visa (NYSE:V) stake by 364,572 shares to 1.14 million valued at $106.99 million in 2017Q2.

30 September 2017
Abbott Laboratories (ABT) Hits a 52-Week High
Following the completion of the transaction, the insider now directly owns 28,806 shares in the company, valued at $1,416,102.96. Moreover, Forbes J M And Ltd Liability Partnership has 0.11% invested in Abbott Laboratories (NYSE: ABT ) for 8,923 shares.

30 September 2017
Thor Industries, Inc. (THO) Earns "Hold" Rating from Stifel Nicolaus
They use historic price data to observe stock price patterns to predict the direction of that price going forward. (NYSE:THO). The average 1-year price target for (CLDR) reveals an average price target of $23 per share. (NYSE:THO) for 585,407 shares.

30 September 2017
Lattice Semiconductor Corporati (NASDAQ:LSCC) Moving Aggressively - Down $0.06
KeyCorp reaffirmed a "hold" rating on shares of ON Semiconductor Corporation in a research note on Tuesday, September 12th. The stock of Lattice Semiconductor Corp (NASDAQ:LSCC) is a huge mover today! Several research firms have commented on ON.